{"analyses":[{"ciLowerLimit":"-7.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.8","estimateComment":"The 95% CI for the difference in response rates was estimated using the Hauck-Anderson.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8911","paramType":"Difference in response rates","paramValue":"-0.49","statisticalMethod":"Chi-squared"},{"ciLowerLimit":"0.56","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.65","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Odds Ratio (OR)","paramValue":"0.96"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.2","upperLimit":"89.5","value":"84.9"},{"groupId":"OG001","lowerLimit":"78.7","upperLimit":"89.1","value":"84.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"205"}],"units":"Participants"}],"description":"Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \\>75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.","dispersionType":"95% Confidence Interval","groups":[{"description":"Eight cycles of rituximab IV infusion (375 mg/m\\^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\\^2) once every 8 weeks for 24 months.","id":"OG000","title":"Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)"},{"description":"First cycle of rituximab IV infusion (375 mg/m\\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.","id":"OG001","title":"Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)"}],"paramType":"NUMBER","populationDescription":"ITT Population.","reportingStatus":"POSTED","timeFrame":"Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)","title":"Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL","type":"SECONDARY","unitOfMeasure":"percentage of participants"}